About this webinar
Recorded On: Wednesday, February 12, 2020
When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. Unfortunately, strong evidence linking specific genetic biomarkers to FDA-approved therapies only exists for a small number of cancers. Thus, most variants require an exploration of clinical practice guidelines, peer-reviewed literature, and large-scale cancer mutation databases to effectively assess the clinical significance of a given mutation.
This webcast explores this new incorporation of Drugs & Trials Annotations in VSClinical's AMP Workflow covering:
- Identification of relevant clinical evidence for drug sensitivity and resistance based on patient biomarkers and tumor type
- Review of clinical trial information including inclusion criteria, trial status, and contact information
- Management of citations associated with relevant, targeted therapies
- Evaluation of a biomarkers clinical evidence tier based on available evidence for drug sensitivity and resistance
Watch on demand
Please enjoy this webcast recording. Should you have any questions about the content covered, please reach out to our team here.